Merck & Co., Inc. (BVMF:MRCK34)

Market Cap	1.35T
Revenue (ttm)	342.33B
Net Income (ttm)	101.44B
Shares Out	n/a
EPS (ttm)	40.27
PE Ratio	13.27
Forward PE	11.34
Dividend	1.58 (2.31%)
Ex-Dividend Date	Sep 12, 2025

Volume	2,755
Average Volume	6,794
Open	67.53
Previous Close	67.53
Day's Range	67.50 - 68.36
52-Week Range	51.60 - 81.69
Beta	0.32
RSI	64.32
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: MRCK34

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD